5. Cinqair

Teva

Active ingredient: reslizumab
Disease: severe eosinophilic asthma
Peak sales estimate: $300 million
Approved: March 23
Company: Teva

The scoop: It wasn’t all that long ago that there were no drugs specifically approved to treat severe eosinophilic asthma. But by the time Teva’s Cinqair came around, GlaxoSmithKline’s Nucala was already on the scene, making it the med to beat. Unfortunately for Teva, GSK may have the edge when it comes to dosing convenience: Nucala is administered subcutaneously, while Cinqair is an intravenous formulation. But that’s not all Teva has to worry about. AstraZeneca pipeline therapy benralizumab—another subcutaneous product—has data in hand that may support less frequent dosing than both its on-market rivals. —Carly Helfand

5. Cinqair

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.